Emerging roles of regulatory T cells in tumour progression and metastasis

被引:69
作者
Halvorsen, Elizabeth C. [2 ,4 ]
Mahmoud, Sahar M. [3 ,4 ]
Bennewith, Kevin L. [1 ,2 ,3 ]
机构
[1] British Columbia Canc Agcy, Dept Integrat Oncol, Vancouver, BC V5Z 1L3, Canada
[2] Univ British Columbia, Interdisciplinary Oncol Program, Vancouver, BC V5Z 1M9, Canada
[3] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada
[4] British Columbia Canc Agcy, Dept Integrat Oncol, Vancouver, BC V5Z 1L3, Canada
基金
加拿大健康研究院;
关键词
Regulatory T cells; Patient prognosis; Metastasis; Metastatic foci development; Therapeutics; BREAST-CANCER METASTASIS; ANTITUMOR IMMUNE-RESPONSES; ENDOTHELIAL-GROWTH-FACTOR; PREDICT POOR SURVIVAL; FOXP3; EXPRESSION; NEOADJUVANT CHEMOTHERAPY; SUPPRESSOR-CELLS; PROGNOSTIC VALUE; TREG CELLS; CYCLOOXYGENASE-2;
D O I
10.1007/s10555-014-9529-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The metastasis of cancer is a complex and life-threatening process that is only partially understood. Immune suppressive cells are recognized as important contributors to tumour progression and may also promote the development and growth of tumour metastases. Specifically, regulatory T cells (Tregs) have been found to promote primary tumour progression, and emerging pre-clinical data suggests that Tregs may promote metastasis and metastatic tumour growth. While the precise role that Tregs play in metastatic progression is understudied, recent findings have indicated that by suppressing innate and adaptive anti-tumour immunity, Tregs may shield tumour cells from immune detection, and thereby allow tumour cells to survive, proliferate and acquire characteristics that facilitate dissemination. This review will highlight our current understanding of Tregs in metastasis, including an overview of pre-clinical findings and discussion of clinical data regarding Tregs and therapeutic outcome. Evolving strategies to directly ablate Tregs or to inhibit their function will also be discussed. Improving our understanding of how Tregs may influence tumour metastasis may lead to novel treatments for metastatic cancer.
引用
收藏
页码:1025 / 1041
页数:17
相关论文
共 157 条
[1]   Host B7x Promotes Pulmonary Metastasis of Breast Cancer [J].
Abadi, Yael M. ;
Jeon, Hyungjun ;
Ohaegbulam, Kim C. ;
Scandiuzzi, Lisa ;
Ghosh, Kaya ;
Hofmeyer, Kimberly A. ;
Lee, Jun Sik ;
Ray, Anjana ;
Gravekamp, Claudia ;
Zang, Xingxing .
JOURNAL OF IMMUNOLOGY, 2013, 190 (07) :3806-3814
[2]   Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients [J].
Ali, H. R. ;
Provenzano, E. ;
Dawson, S-J ;
Blows, F. M. ;
Liu, B. ;
Shah, M. ;
Earl, H. M. ;
Poole, C. J. ;
Hiller, L. ;
Dunn, J. A. ;
Bowden, S. J. ;
Twelves, C. ;
Bartlett, J. M. S. ;
Mahmoud, S. M. A. ;
Rakha, E. ;
Ellis, I. O. ;
Liu, S. ;
Gao, D. ;
Nielsen, T. O. ;
Pharoah, P. D. P. ;
Caldas, C. .
ANNALS OF ONCOLOGY, 2014, 25 (08) :1536-1543
[3]   Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3 [J].
Allan, Sarah E. ;
Song-Zhao, George X. ;
Abraham, Thomas ;
McMurchy, Alicia N. ;
Levings, Megan K. .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2008, 38 (12) :3282-3289
[4]   Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs [J].
Allard, Bertrand ;
Pommey, Sandra ;
Smyth, Mark J. ;
Stagg, John .
CLINICAL CANCER RESEARCH, 2013, 19 (20) :5626-5635
[5]   A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer [J].
Aruga, Tomoyuki ;
Suzuki, Eiji ;
Saji, Shigehira ;
Horiguchi, Shin-Ichirou ;
Horiguchi, Kazumi ;
Sekine, Susumu ;
Kitagawa, Dai ;
Funata, Nobuaki ;
Toi, Masakazu ;
Sugihara, Kenichi ;
Kuroi, Katsumasa .
ONCOLOGY REPORTS, 2009, 22 (02) :273-278
[6]   Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma:: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes [J].
Audia, S. ;
Nicolas, A. ;
Cathelin, D. ;
Larmonier, N. ;
Ferrand, C. ;
Foucher, P. ;
Fanton, A. ;
Bergoin, E. ;
Maynadie, M. ;
Arnould, L. ;
Bateman, A. ;
Lorcerie, B. ;
Solary, E. ;
Chauffert, B. ;
Bonnotte, B. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 150 (03) :523-530
[7]   Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers [J].
Badoual, C ;
Hans, S ;
Rodriguez, J ;
Peyrard, S ;
Klein, C ;
Agueznay, NE ;
Mosseri, V ;
Laccourreye, O ;
Bruneval, P ;
Fridman, WH ;
Brasnu, DF ;
Tartour, E .
CLINICAL CANCER RESEARCH, 2006, 12 (02) :465-472
[8]   Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse [J].
Bates, Gaynor J. ;
Fox, Stephen B. ;
Han, Cheng ;
Leek, Russell D. ;
Garcia, Jose F. ;
Harris, Adrian L. ;
Banham, Alison H. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5373-5380
[9]   The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 [J].
Bennett, CL ;
Christie, J ;
Ramsdell, F ;
Brunkow, ME ;
Ferguson, PJ ;
Whitesell, L ;
Kelly, TE ;
Saulsbury, FT ;
Chance, PF ;
Ochs, HD .
NATURE GENETICS, 2001, 27 (01) :20-21
[10]  
BERENDT MJ, 1980, J EXP MED, V151, P69, DOI 10.1084/jem.151.1.69